GlassScriptPhysician profile
Paul Gilreath
NPI 1124229117
$9,226.27
in general payments reported to CMS, 2019-2025
39 companies · $1,925 in 2025
The $1,925 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,285 · 2020: $1,918 · 2021: $2,043 · 2022: $1,345 · 2023: $149 · 2024: $561 · 2025: $1,925.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,636.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,635.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,961.95 | 2019-2025 | Zilbrysq, Nayzilam, Briviact |
| Supernus Pharmaceuticals, INC. | $984.37 | 2019-2022 | |
| Boston Scientific Corporation | $715.65 | 2019-2025 | Infinion 16, Infinion 16, Linear |
| Abbvie INC. | $558.08 | 2021-2025 | |
| Sk Life Science, INC. | $429.77 | 2020-2025 | |
| Teva Pharmaceuticals USA, INC. | $402.96 | 2019-2025 | Ajovy |
| Adamas Pharmaceuticals, INC. | $373.46 | 2019-2021 | |
| Lilly USA, LLC | $373.11 | 2019-2025 | Kisunla |
| Eisai INC. | $321.72 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $317.55 | 2019-2022 | |
| Pfizer INC. | $295.49 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $281.34 | 2020-2021 | |
| Amgen INC. | $278.29 | 2019-2025 | Uplizna |
| Lundbeck LLC | $244.07 | 2020-2025 | Vyepti |
| Csl Behring | $214.35 | 2024-2025 | Hizentra |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Gilreath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.